Neuraxis Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $5.3M+97.9% YoYTTM through 30 Jun 2026
Net Income -$7.7MTTM through 30 Jun 2026
Free Cash Flow -$5.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 84.2% |
| EBITDA Margin | -143.7% |
| Operating Margin | -219.4% |
| Net Margin | -144.4% |
Returns
-229.5%ROE
-121.8%ROA
Balance Sheet Health
Debt / Equity0.04x
Current Ratio2.10x
Net Debt-$4.8Mnet cash position
Cash & Equivalents$8.3M
Quality Metrics
Altman Z-Score5.89
Piotroski F-Score4 / 9
FCF Margin-106.0%
Earnings-Beat Rate33.3%
Multi-Year Trend
RevenueFY2025: $3.6M
Diluted EPS-$0.76TTMFY2025: $-0.86
Dividend
No dividend
Capital Allocation
R&D Spend$645.3K
Capex Intensity0.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| IB-Stim | $3.6M | +32.9% | View detailsExpected to benefit from Category I CPT code effective January 1, 2026, driving a shift to higher-margin full reimbursement sales. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.